Can autoimmune and allergic-type immune activation cause mild neutropenia?

Neutropenia in the context of autoimmune and allergic-type immune activation is a recognized clinical phenomenon resulting from distinct yet overlapping immunological pathways. Research confirms that both peripheral destruction and bone marrow suppression play critical roles in reducing absolute neutrophil counts (ANC).

Clinical and mechanistic evidence in autoimmunity

Autoimmune conditions are established drivers of mild to moderate neutropenia, primarily through antibody-mediated destruction.

• Autoantibody-mediated clearance: The production of anti-neutrophil IgG autoantibodies leads to the opsonization of mature neutrophils. These tagged cells are subsequently removed by macrophages in the spleen, liver, and bone marrow via antibody-dependent cellular phagocytosis (ADCP).
• Secondary autoimmune associations: In patients with adult-onset autoimmune neutropenia (AIN), approximately 31% have an underlying autoimmune comorbidity. For example, in Hashimoto’s thyroiditis, anti-neutrophil antibodies are detected in 37% of neutropenic patients.
• Polyclonal activation: While specific antibodies (like anti-TPO) do not appear to cross-react with neutrophils directly, their elevation often correlates with the presence of anti-neutrophil antibodies, reflecting a state of generalized B-cell dysregulation and immune activation.

Mechanistic insights into allergic-type suppression

While less common than autoimmune destruction, allergic-type (Type 2) immune activation can suppress neutrophil levels through cytokine signaling that alters bone marrow production.

• Lineage skewing: Type 2 cytokines, including IL-4, IL-5, and IL-13, prioritize the differentiation of hematopoietic stem cells (HSCs) into eosinophilic and basophilic lineages. This competition for progenitor cells can lead to a relative decrease in neutrophilic myelopoiesis.
• Regulatory suppression: Cytokines such as IL-10, which are often elevated in allergic and regulatory immune contexts, can suppress the "emergency granulopoiesis" typically driven by Th1 or Th17 responses.
• Hypersensitivity correlations: Clinical observations in drug-induced hypersensitivity reactions (e.g., to methimazole) frequently show a concurrent rise in eosinophils and a disappearance of neutrophil lineages in the bone marrow, supporting the concept of a cytokine-driven shift in cell production.

Bottom line

The claim is well-supported by evidence for autoimmune-mediated destruction and is mechanistically plausible for allergic-type cytokine suppression. Autoimmune neutropenia is typically driven by IgG-mediated phagocytosis, while allergic states may suppress neutrophil counts by skewing bone marrow production toward eosinophilic lineages. For a 57-year-old female with suspected immune activation, these mechanisms provide a robust scientific basis for observing mild neutropenia.